Dimensional Fund Advisors LP Boosts Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 630,226 shares of the specialty pharmaceutical company's stock after purchasing an additional 21,053 shares during the quarter. Dimensional Fund Advisors LP owned 3.00% of ANI Pharmaceuticals worth $40,132,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals during the second quarter worth about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the second quarter valued at approximately $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $106,000. ADAR1 Capital Management LLC acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $132,000. Finally, Clear Street Markets LLC bought a new stake in ANI Pharmaceuticals during the fourth quarter worth $140,000. Institutional investors own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the completion of the sale, the chief operating officer now directly owns 671,620 shares of the company's stock, valued at $42,567,275.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 26,007 shares of company stock worth $1,642,990 in the last quarter. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Trading Down 0.3 %

NASDAQ ANIP traded down $0.18 during mid-day trading on Tuesday, reaching $59.48. 191,331 shares of the stock were exchanged, compared to its average volume of 214,763. The stock has a market cap of $1.25 billion, a P/E ratio of 37.18 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The stock has a 50 day simple moving average of $60.60 and a 200-day simple moving average of $63.36.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business had revenue of $138.00 million during the quarter, compared to analysts' expectations of $129.09 million. During the same quarter last year, the firm posted $1.06 earnings per share. The firm's revenue was up 18.5% on a year-over-year basis. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current year.

Analyst Ratings Changes

ANIP has been the topic of several recent analyst reports. Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. StockNews.com downgraded ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Finally, Truist Financial reissued a "hold" rating and set a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $78.80.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.